← Oncology Approval Tracker

FDA DECISION ·

Poherdy

pertuzumab-dpzb · Shanghai Henlius Biologics

Biosimilar approvalBiosimilarBreast cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

An interchangeable biosimilar to Perjeta for approved HER2-positive breast cancer uses with trastuzumab and chemotherapy: previously untreated metastatic disease, eligible neoadjuvant disease, and high-risk early disease in the adjuvant setting.

LAMPGEN ANALYSIS

Why it matters

This was the first FDA-approved pertuzumab biosimilar, with interchangeability determined at approval.

What research teams should watch

Update product-level ordering, lot traceability, and cardiac assessment workflows before formulary use.

PRIMARY RECORDS

Sources